Literature DB >> 27351715

Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.

Fabio Efficace1, Franco Mandelli2, Paola Fazi2, Cristina Santoro3, Gianluca Gaidano4, Francesco Cottone2, Alessandra Borchiellini5, Monica Carpenedo6, Maria Pina Simula7, Valeria Di Giacomo8, Micaela Bergamaschi9, Iolanda Donatella Vincelli10, Francesco Rodeghiero11, Marco Ruggeri12, Laura Scaramucci13, Alessandro Rambaldi14, Nicola Cascavilla15, Fabio Forghieri16, Annamaria Petrungaro17, Paolo Ditonno18, Giovanni Caocci19, Sonia Cirrincione20, Maria Gabriella Mazzucconi3.   

Abstract

The main objective of this study was to compare health-related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic patients). Fatigue was also investigated as a secondary objective. Overall, 424 adult patients were enrolled in a multicenter observational study and the control group consisted of a representative sample from the general population. Propensity score matching plus further multivariate linear regression adjustment was used to compare HRQOL outcomes between pITP patients and general population. Mean age of patients was 54 years. Of those with HRQOL assessment, 99 patients (23.6%) were newly diagnosed, 53 (12.6%) were persistent, and 268 (63.8%) were chronic pITP patients. Comparison by patient group versus their respective peers in the general population revealed greater impairments in persistent pITP patients. Persistent pITP patients reported clinically meaningful impairments in physical functioning (-15; 95% CI -24.1 to -5.8; P = 0.002), social functioning (-15.3; 95% CI -25.5 to -5.1; P = 0.004), role physical (-28.4; 95% CI -43.1 to -13.7; P < 0.001), role emotional (-23.9; 95% CI -40.1 to -7.7; P = 0.004), and mental health scales (-11.3; 95% CI -21.2 to -1.4; P = 0.026) of the SF-36 questionnaire. Higher fatigue severity was associated with lower physical and mental HRQOL outcomes. Our findings suggest that the burden of the disease and treatment might depend on the disease phase and that persistent pITP patients are the most vulnerable subgroup. Am. J. Hematol. 91:995-1001, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27351715     DOI: 10.1002/ajh.24463

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

Review 2.  The Extensive Regulation of MicroRNA in Immune Thrombocytopenia.

Authors:  Yuerong Zhao; Siyuan Cui; Yan Wang; Ruirong Xu
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

3.  Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features.

Authors:  Abraham Z Cheloff; David J Kuter; Hanny Al-Samkari
Journal:  Res Pract Thromb Haemost       Date:  2020-06-21

4.  Health-Related Quality of Life and Burden of Fatigue in Chinese Patients with Immune Thrombocytopenia: A Cross-Sectional Study.

Authors:  Ran Yang; Hao Yao; Lin Lin; Jian-Min Ji; Qun Shen
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

Review 5.  Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP).

Authors:  Anne Zufferey; Rick Kapur; John W Semple
Journal:  J Clin Med       Date:  2017-02-09       Impact factor: 4.241

Review 6.  The Need for Comprehensive Care for Persons with Chronic Immune Thrombocytopenic Purpura.

Authors:  Kristin T Ansteatt; Chanel J Unzicker; Marsha L Hurn; Oluwaseun O Olaiya; Diane J Nugent; Michael D Tarantino
Journal:  J Blood Med       Date:  2020-12-17

7.  Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.

Authors:  Alicia Rovó; Nathan Cantoni; Kaveh Samii; Axel Rüfer; Giedre Koenen; Sandra Ivic; Davide Cavanna; Rudolf Benz
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.240

8.  Anti-glycoprotein antibodies and sequestration pattern of indium-labeled platelets in immune thrombocytopenia.

Authors:  Sufia N Amini; Leendert Porcelijn; Annemieke Sobels; Marina Kartachova; Masja de Haas; Jaap Jan Zwaginga; Martin R Schipperus
Journal:  Blood Adv       Date:  2022-03-22

9.  [Predictors of fatigue among individuals with primary immune thrombocytopenia in China].

Authors:  Y Li; M E Lyu; Y T Hao; B Y Sun; Y T Huang; R F Fu; F Xue; X F Liu; L Zhang; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-05-14

Review 10.  Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia.

Authors:  Siyu Sun; Rolf T Urbanus; Hugo Ten Cate; Philip G de Groot; Bas de Laat; Johan W M Heemskerk; Mark Roest
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.